Retinoblastoma survival & prognosis — what parents need to know

Retinoblastoma has one of the most favourable survival outlooks of any childhood cancer when it is diagnosed while the tumour is still confined to the eye or eyes. In high-income settings with access to specialist care, the overall survival rate for children with intraocular (stage confined to the eye) retinoblastoma is very high. However, retinoblastoma that has spread beyond the eye — to the optic nerve, orbit, or to distant sites — has a more serious outlook and requires intensive multimodal treatment.

In India, outcomes are closely linked to how early the diagnosis is made, which is why any new squint, white pupil reflex, or loss of vision in a young child should prompt immediate specialist evaluation. Early diagnosis is the single most powerful factor in both saving life and preserving vision.

Retinoblastoma can affect one eye (unilateral) or both eyes (bilateral). Bilateral retinoblastoma almost always has a hereditary cause — a mutation in the RB1 gene that is present in every cell of the child's body. Unilateral retinoblastoma is more common and is often non-hereditary (though a minority of unilateral cases are also caused by a germline RB1 mutation).

From a survival standpoint, bilateral disease is not inherently more dangerous than unilateral disease if it is detected early; however, children with hereditary retinoblastoma have a lifelong increased risk of developing second cancers, particularly osteosarcoma, and need long-term follow-up. Genetic counselling is essential for all families where retinoblastoma is diagnosed.

The most important factor shaping retinoblastoma prognosis is whether the tumour has spread beyond the eye. Within the eye, tumours are classified using the International Classification of Retinoblastoma (ICRB) as Groups A through E, with Group A being small tumours away from critical structures and Group E being the most advanced, filling most of the eye. Group A and B tumours can often be treated with eye-preserving approaches; Group D and E tumours carry a higher risk of requiring removal of the eye.

The extent of optic nerve involvement and whether cancer cells have reached the choroid (the vascular layer of the eye) are also important — these features on the pathology report after enucleation guide whether additional chemotherapy is needed. Prompt referral to a centre experienced in retinoblastoma management significantly influences what treatment options are available.

Leukocoria — a white or cat's-eye pupil reflex, often first noticed in a photograph when the flash illuminates the eye — is the most common presenting sign of retinoblastoma. It occurs when light reflects off the white tumour growing inside the eye rather than returning the normal red-eye reflex from the blood-rich retina.

Leukocoria is not always retinoblastoma — other conditions such as cataract, certain retinal disorders, or infection can cause a similar appearance — but it should always be treated as an urgent red flag requiring same-week ophthalmology assessment. Parents who notice a white reflex in one or both of their child's eyes should not wait for a routine appointment. Any delay in evaluation when retinoblastoma is the cause directly reduces the chance of saving the eye and can affect survival.

Eye salvage — preserving the affected eye — is now an achievable goal for many children with retinoblastoma, particularly when the tumour is diagnosed at an early group (A, B, or C). Advances in intra-arterial chemotherapy, where a concentrated dose of chemotherapy is delivered directly into the ophthalmic artery supplying the eye, have significantly improved the chances of treating tumours without removing the eye. Intravitreal chemotherapy (injection directly into the vitreous cavity) is used for tumours that have seeded into the vitreous gel. For very small tumours, local treatments such as laser photocoagulation or cryotherapy can destroy the tumour directly.

The goal of treatment is always to save life first, then the eye if possible, and then vision within the eye. Whether eye salvage is realistic for your child depends on the tumour group at diagnosis — your child's specialist will give you a frank, honest assessment.

All children diagnosed with retinoblastoma should have genetic testing of the RB1 gene — testing the tumour tissue and, ideally, the child's blood. If a germline (blood) RB1 mutation is identified, it means the mutation is present in every cell of the child's body. Siblings and parents should also be tested so that any affected relatives can be monitored.

Children with a germline RB1 mutation need regular long-term surveillance even after successful treatment, because they carry a higher lifetime risk of developing a second primary tumour. Genetic counselling helps families understand what the results mean for other children the parents may have in the future. Testing is currently not universally available in all parts of India, but specialist paediatric oncology centres coordinate referrals to genetics services.